Toyota Industries Corporation/ US8923301019 /
29/05/2024 18:50:32 | Diferencia -0.4350 | Volumen | Bid- | Ask- | Máximo del día | Price Change Band |
---|---|---|---|---|---|---|
93.2300USD | -0.46% | 1,913 Volumen de negocios: 107,927.3375 |
-Volumen de oferta: - | -Tamaño/ Volumen/ Formato de Ask: - | 93.4875 | 93.0850 |
GlobeNewswire
10:28
Delphos Advises MPC Energy Solutions on a USD 34 million Non-Recourse Project Financing for the Cons...
GlobeNewswire
10:00
DRCT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Direct Digital Holdings Inc. I...
GlobeNewswire
10:00
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Sub...
GlobeNewswire
10:00
EQIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Equinix, Inc. Investors with S...
GlobeNewswire
10:00
CMP INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Compass Minerals International,...
GlobeNewswire
10:00
ASTS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AST SpaceMobile, Inc. Investor...
GlobeNewswire
10:00
LNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lincoln National Corporation In...
GlobeNewswire
10:00
ADSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Autodesk, Inc. Investors with ...
GlobeNewswire
10:00
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of D...
GlobeNewswire
9:42
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
9:01
Persistent Systems Selects Zscaler to Launch Technology Modernization and Renewable Energy Initiativ...
GlobeNewswire
9:00
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer I...
GlobeNewswire
9:00
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutrace...
GlobeNewswire
8:35
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
GlobeNewswire
8:30
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimi...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página